Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan.

British journal of clinical pharmacology - 1 Nov 1996

Barbhaiya R H, Buch A B, Greene D S

Abstract excerpt

1. The single and multiple dose pharmacokinetics of nefazodone (NEF) and its active metabolites hydroxynefazodone (HO-NEF) and m-chlorophenyl-piperazine (mCPP) were evaluated in subjects classified as extensive metabolizers (EM) or poor metabolizers (PM) of dextromethorphan. 2. In a parallel design study, 10 subjects from each phenotype received either 50 mg or 200 mg oral doses of NEF as single doses on Day 1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP2D6
Share to Dextromethorphan

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phenotype

Share to Piperazines

Source

Identifiers

PMID: 8951188
DOI: 10.1111/j.1365-2125.1996.tb00112.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan.PMID 8951188Read ↗

Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition.Semantic proximity Read ↗

Analysis of pharmacokinetic parameters for assessment of dextromethorphan metabolic phenotypes.Semantic proximity Read ↗

CYP2D6 genotype and phenotyping by determination of dextromethorphan and metabolites in serum of healthy controls and of patients under psychotropic medication.Semantic proximity Read ↗

Dose dependency of dextromethorphan for cytochrome P450 2D6 (CYP2D6) phenotyping.Semantic proximity Read ↗

Psychotropic effects of dextromethorphan are altered by the CYP2D6 polymorphism: a pilot study.Semantic proximity Read ↗

Development of a rapid and sensitive high-performance liquid chromatographic method to determine CYP2D6 phenotype in human liver microsomes.Semantic proximity Read ↗

Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation.Semantic proximity Read ↗

Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers.Semantic proximity Read ↗

Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects.Semantic proximity Read ↗

CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations.Semantic proximity Read ↗

Single-point plasma or urine dextromethorphan method for determining CYP3A activity.Semantic proximity Read ↗

The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: in vitro studies using human liver microsomes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.